Showing 1471-1480 of 1743 results for "".
- Leo Pharma's Adbry Reduces S. aureus Skin Colonization in Kids With ADhttps://practicaldermatology.com/news/leo-pharmas-adbry-reduces-s-aureus-skin-colonization-in-kids-with-ad/2461616/Leo Pharma’s Adbry (tralokinumab-ldrm) significantly reduced the abundance of Staphylococcus aureus in the lesional and non-lesional skin of adolescents with atopic dermatitis (AD) after 16 weeks, according to new data presented at the American Academy of Dermatology
- EMA Accepts Marketing Authorization Applications for UCB's Bimekizumab in Psoriatic Arthritis and Axial Spondyloarthritishttps://practicaldermatology.com/news/ema-accepts-marketing-authorization-applications-for-ucbs-bimekizumab-in-psoriatic-arthritis-and-axial-spondyloarthritis/2461354/The European Medicines Agency (EMA) has accepted for regulatory review the two marketing authorization applications for UCB's bimekizumab for the treatment of adult patients with active psoriatic arthritis (PsA), and adult patients with active axial spondyloarthritis (axSpA). &ldquo
- Artemis Health, Zerigo Health Partner to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditionshttps://practicaldermatology.com/news/artemis-health-zerigo-health-partner-to-help-employers-and-health-plans-better-evaluate-and-manage-chronic-autoimmune-skin-conditions/2461335/Artemis Health and Zerigo Health are joining forces to helps employers, advisors, and health plans evaluate and manage benefits for their members with chronic autoimmune skin conditions such as psoriasis and atopic dermatitis. “Benefits leaders are inundated by hundreds of point s
- Psoriasis, Other Autoimmune Diseases Up Risk for CVDhttps://practicaldermatology.com/news/psoriasis-other-autoimmune-diseases-up-risk-for-cvd/2461323/Earlier research has suggested associations between some autoimmune disorders and a higher risk of cardiovascular disease, and now, a new study shows that nineteen of the most common autoimmune disorders seem to increase risk for developing heart disease. Patients with autoim
- First Austrian Skin Cancer Patients Treated with Rhenium-SCT in New Studyhttps://practicaldermatology.com/news/first-austrian-skin-cancer-patients-treated-with-rhenium-sct-in-new-study/2461110/The first Austrian patients have been treated in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT– for the treatment of non-melanoma skin cancer), according to OncoBeta GmbH. "This is an important step for better u
- Updates from EADV: Cosentyx Autoinjector, Genetic Variants Linked to Genital Warts, At-Home PDT Shows Promisehttps://practicaldermatology.com/news/updates-from-eadv-cosentyx-autoinjector-genetic-variants-linked-to-genital-warts-at-home-pdt-shows-promise/2460939/• Treatment with Cosentyx®(secukinumab) 300mg in a 2mL autoinjector (UnoReady® pen) was more effective than placebo and achieved high patient satisfaction compared to two 150mg pre-filled syringes, according to Phase 3b data presented
- FDA Approves Galderma's Restylane Defyne for Chin Augmentationhttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-defyne-for-chin-augmentation/2460676/The U.S. Food and Drug Administration (FDA) has approved Restylane Defyne for the augmentation and correction of mild to moderate chin retrusion in adults over the age of 21. Restylane Defyne is a hyaluronic acid (HA) dermal filler that was first approved in 201
- Industry Responds to COVID-19: Cyrex Labs Offers Multiple Autoimmune Reactivity Screenhttps://practicaldermatology.com/news/industry-responds-to-covid-19-pyrex-labs-offers-multiple-autoimmune-reactivity-screen/2460484/With the risks associated with COVID-19 and because those with one autoimmune disease have a 25 percent chance of developing another, specialists say it is critical for those with autoimmune disease to use safety measures, good eating habits, and self-care to avoid contracting this or any virus.&
- FDA Approves Galderma's Restylane Kysse for Lip Augmentation and Upper Perioral Rhytidshttps://practicaldermatology.com/news/fda-approves-galdermas-restylane-kysse-for-lip-augmentation-and-upper-perioral-rhytids-1/2460374/The FDA has approved Galderma'a Restylane Kysse for lip augmentation and the correction of upper perioral rhytids in adults over the age of 21. Restylane Kysse is the first hyaluronic acid (HA) filler specifically indicated for the lips using XpresHAn Technology globally referred to as the OB
- Novartis Terminates Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo in Mutual Agreementhttps://practicaldermatology.com/news/novartis-terminates-sale-of-sandoz-us-generic-oral-solids-dermatology-portfolio-to-aurobindo-in-mutual-agreement/2460332/In a mutual agreement with Aurobindo Pharma USA Inc., Novartis has terminated the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within ant